FISCAL ESTIMATE FORM				1999 Session
		LRB # - 457	76/1	
⊠ ORIGINAL	☐ UPDATED		TION # AB 815	
☐ CORRECTED	☐ SUPPLEMENTAL	- Admin. Rule #		
Subject	Andinana Daninia		,	
Prescription Drug Assistance for M	/ledicare Recipier	nts 		
Fiscal Effect				
State: ☐ No State Fiscal Effect			ı	
Check columns below only if bill mal		ation	1	y be possible to Absorb
or affects a sum sufficient app	ropriation.		Within Agency's Bud	lget □ Yes ☒ No
☐ Increase Existing Appropriation	□ Increase	Existing Revenues		
☐ Decrease Existing Appropriation		Existing Revenues	☐ Decrease Costs	
		9		
Local: ⊠ No local government cost	ts			
1. ☐ Increase Costs	3. 🗆 Increase	e Revenues	5. Types of Local Go	vernmental Units Affected:
☐ Permissive ☐ Mandator	y 🔲 Perm	nissive	☐ Towns ☐ Vill	ages Cities
2. Decrease Costs	4. Decreas		☐ Counties ☐ Oth	
☐ Permissive ☐ Mandator	y ☐ Perm		☐ School Districts	☐ WTCS Districts
Fund Sources Affected			ed Ch. 20 Appropriations	
⊠ GPR □ FED ⊠ PRO	□PRS □ SEG		5 (4) (a), 20.435 (4) (j), 20.43 5 (4) (o)	5 (4) (b), 20.435 (4) (n),
Assumptions Used in Arriving at Fiscal	Estimate:			
See Attached Narrative.				
		•		
,				
				,
		•		
Long-Range Fiscal Implications:				
				T
Prepared By: / Phone # / Agency	Name A	uthorized Signature (Te	leginone No.	Date
Richard T. Chao / 267-0356		- John D	West !	2-29-00
DHFS/OSF	J	ohn Kiesow, 266-96	322	166100

LRB4576/1

Bill Summary

The bill mandates that as a condition of participation in the State's Medicaid program, pharmacies may not charge program recipients an amount for certain prescription drugs for outpatient care that exceeds the Average Wholesale Price (AWP) minus 11% or the Maximum Allowable Cost (MAC), as determined by the Department, whichever is lower, for providing that drug, plus a dispensing fee. Prescription drugs covered in the program are for the treatment of a chronic condition as defined in the bill. Program eligibility includes persons who are eligible for Medicare, ineligible for Medicaid and whose incomes do not exceed 185% of the Federal Poverty Level.

The Department is directed to enter with drug manufacturers into rebate agreements, which are modeled on federal Medicaid rebate agreements. The Department must in turn pay the rebate payments to pharmacies that have reduced charges for prescription drugs for the eligible persons. In addition, the bill restricts the Department from subjecting drug manufactures to prior authorization requirements in the Medicaid program from January 01, 2001 through July 01, 2003. Specifically, the Department is prohibited from requiring Medicaid prior authorization for: 1) All prescription drugs used for the treatment of chronic diseases, including those currently on prior authorization; and 2) All new drugs regardless of type, which enter the market after January 01, 2001. The bill also appropriates \$1.0 million per year for the administration of the program.

Fiscal estimate

Administrative expenses

The bill appropriates \$1,000,000 in general purpose revenues (GPR) for administration of the prescription drug assistance program. This funding level does not cover the full cost of administering the plan. Administering this program includes eligibility determination for over 300,000 people each year, developing a system that can collect transaction data from pharmacies, administering lines of communication and assistance for recipients and providers, production and distribution of enrollee identification cards, and negotiating and collecting rebates from manufacturers. The Department estimates the annual administrative expenditures to be \$2.0 million per year of which \$1.5 million will be allocated for eligibility verification and \$0.5 million for other administrative services. The Department anticipates the use of the Medicaid Point of Sale (POS) Information System to collect necessary data from pharmacies, which will be used to determine the amount and distribution of the manufacturer drug rebates. It is estimated that \$1.5 million dollars will be needed in one-time information systems modifications.

In addition, the Department estimates that an additional 3.0 FTE will be needed to administer the program. These positions include a program administrator, an information systems analyst, and a pharmacy consultant. The estimated total annual cost for these positions is \$177,735 with one-time costs of \$14,400. A table summarizing the costs of the necessary positions is attached.

Cost of the Program

The estimated annualized net cost of the program is expected to be \$24,948,900 AF. This figure includes \$13,389,500 FED and \$9,381,700 GPR in increased expenses due to the loss of prior authorization authority by the Department and \$2,177,735 GPR in annual administrative expenses. It is estimated that the Department will collect \$9,246,900 PRO in manufacturer's rebates, which will then be distributed to the pharmacies. As a result, the net fiscal effect of the rebates and subsequent distribution is zero, not including the cost of rebate administration. A more detailed explanation of the fiscal estimates can be found in the attached worksheets.

Major Assumptions

- ✓ Uses current Medicaid drug expenditure trends, which indicate that expenditures will increase by approximately 15% per year.
- Assumes a 17% rebate from drug manufacturers. However, unlike the Medicaid program, there is no federal law mandating that manufacturers provide rebates for this type of program. In addition, this estimate assumes that it will be possible to calculate and distribute these rebates to the pharmacies. However,

current federal regulations have strict prohibitions on disclosure of rebate information. It is unclear if the Department will be able to carry out its mandated duties as specified in the bill.

- ✓ The Department anticipates using the Medicaid Point of Sale (POS) Information System to collect rebate data and distribute rebate revenues. Although the Department will not be responsible for processing drug claims, the bill mandates that the Department collect data for rebate calculations from pharmacies that participate in the program. Data collected through the Medicaid POS system will be used to determine how collected rebates will be distributed and to facilitate resolution of rebate disputes. The complexity of collection and analysis of this data will require an advanced system such as the Medicaid POS system. In addition, because federal rebate information is proprietary information, it is uncertain if the federal government will permit an outside vendor such as a Pharmacy Benefits Manager (PBM) to engage in these activities.
- ✓ Assumes increased Medicaid costs for: 1) Drugs for chronic conditions that are currently subject to prior authorization requirements, which will need to be removed from prior authorization requirements after the program begins on January 1, 2001; 2) Existing drugs which the Department intended to place on prior authorization after January 1, 2001; and 3) All new drugs entering the market after January 1, 2001, which the Department would have placed on prior authorization.
- ✓ Assumes no additional administrative cost for monitoring and compliance functions. It is not currently possible to evaluate the scope of the Departments responsibilities. However, these duties could require significant additional expenses.
- ✓ Assumes no "crowd out" of current insurance coverage for prescription drugs for the elderly. However, because the proposed program provides benefits with no enrollment cost, it is possible that elderly individuals who currently have insurance coverage for drugs, e.g. Medigap prescription drug riders, may choose to drop or modify their current insurance coverage.
- ✓ A program participation rate of 75% for all eligible people with no "ramp up" for enrollment.
- ✓ An annual out-of-pocket drug cost of \$1,200 for recipients without insurance.
- ✓ Assumes 38% of out-of-pocket drug expenditures attributed to chronic disease drugs.
- ✓ A 24% discount in Medicaid reimbursement levels (AWP-11%) below retail prices.
- ✓ The out-of-pocket expense of recipients with drug coverage is 35% of expenses of recipients without drug coverage.

ESTIMATED INCREASED EXPENDITURES DUE TO DEPARTMENT INABILITY TO REQUIRE PRIOR AUTHORIZATION PROCEDURES FOR PRESCRIPTION DRUGS AS DESCRIBED IN LRB4576/1

			CY 2001		CY 2002	C	Y 2003 (0.5 years)	All Years (2.5 years)
Drugs v 1/1/01	vith PA as of						~	
	ALL FUNDS	\$	14,887,147	\$	17,120,219	\$	9,844,126	\$ 41,851,493
	GPR	\$	6,133,505	\$	7,053,530	\$	4,055,780	\$ 17,242,815
	FED	\$	8,753,643	\$	10,066,689	\$	5,788,346	\$ 24,608,678
Drugs v 1/1/02	vith PA as of							
	ALL FUNDS			\$	9,572,386	\$	5,504,122	\$ 15,076,508
	GPR	_		\$ \$ \$	3,943,823	\$	2,267,698	\$ 6,211,521
	FED			\$	5,628,563	\$	3,236,424	\$ 8,864,987
Total								•
	ALL FUNDS	\$	14,887,147	\$	26,692,605	\$	15,348,248	\$ 56,928,001
	GPR	\$	6,133,505	\$	10,997,353	\$	6,323,478	\$ 23,454,336
	FED	\$	8,753,643	\$	15,695,252	\$	9,024,770	\$ 33,473,664
							ualized Costs	
						(2.5	years)	
							ALL FUNDS	22,771,200
							GPR	9,381,735
							FED	\$ 13,389,466
						Adm	nin (GPR)	\$ 2,177,735
						Tota	al Annualized	\$ 24,948,936
							ualized GPR	\$ 11,559,470

Population and Recipient Benefit Estimates

Estimates of Potential Enrollees

800,000	Approximate Medicare population in the state
309,600	Total potential eligibles (38.7% of total)
109,900	Potential eligibles without drug coverage (35.5% of total)
140,500	Potential eligibles with drug coverage (64.5% of total)

Drug Expenditures for Recipients Without Drug Coverage

109,900	Potential eligibles without drug coverage
82,425	Enrollees without drug coverage (75% participation rate)
\$1,587	Annual drug cost per enrollee (\$1,200 in 1999, inflated to \$1,587 in 2001)
\$600	Annual drug cost for drugs used primarily for chronic conditions (37.8% of total)
\$456	Annual drug cost for drugs per enrolleee at AWP - 11% (24% discount)
\$144	Amount of discount received per enrollee
\$37,578,659	Total drug cost for drugs used primarily for chronic conditions
\$11,866,945	Total amount of discounts received

Drug Expenditures for Recipients With Drug Coverage

Potential eligibles without drug coverage
Enrollees without drug coverage (75% participation rate)
Annual drug cost per enrollee (35% of \$1,200 in 1999, inflated to \$1,587 in 2001)
Annual drug cost for drugs used primarily for chronic conditions (37.8% of total)
Annual drug cost for drugs per enrolleee at AWP - 11% (24% discount)
Amount of discount received per enrollee
Total drug cost for drugs used primarily for chronic conditions
Total amount of discounts received

Total Drug Expenditures, Discounts and Rebates

\$54,393,313	Total drug cost for chronic conditions for all enrollees
\$17,176,836 \$80	Total amount of discounts received by all enrollees Average Annual Discount per enrollee
\$9,246,863	Annual rebate collections (assumes rebates at 17% of total drug costs)

Administrative Expenses LRB 4576/1

Personnel

Classification		FTE	\$/hr	Salary	Fringe	<i>d</i>	1100	i E		
					9	5	Kent	Services	Total	One-time
Pharmacy Practices Consultant		1.00 \$	22.96	22.96 \$ 47,746 \$	\$ 866,91	1,200 \$	2,000	\$3,100	\$71.044 \$	\$ 4 800
IS PAL-Senior		1.00 \$	17.31 \$	\$ 36,005 \$	12,818 \$	1,200 \$	2,000	\$3,100	\$55,123	
Program and Planning Anaylst 5		1.00 \$	16.05 \$	\$ 33,384 \$	11,885 \$	1,200 \$	2,000		\$51,569	\$ 4.800
	Total 3.	3.00		117,135 \$	\$ 117,135 \$ 41,700 \$	3,600 \$	6,000	6,000 \$ 9,300 \$177,735 \$	\$177,735	\$ 14,400

\$ 2,000,000 \$ 177,735	\$ 2,177,735	\$ 1,500,000 \$ 14,400	\$ 1.514.400
Annual Recipient Administrative Expense Annual Personnel Expense	Total On-going Administrative Expenses	One-time Systems Modification One-time Staff Expenses	Total One-time Administrative Expenses

FIS	CAL ESTIMATE WORKSHEET	Detailed Estim	nate of Annual Fiscal Eff	ect	1999 Session
	☑ ORIGINAL ☐ UPDATED	LRB #-4576	6/1		Admin. Rule #
	☐ CORRECTED ☐ SUPPLEMENTAL	INTRODUC	TION # AB 8	15	
Sub Pre	ject scription Drug Assistance for Me	dicare Recipients			
I.	One-time Costs or Revenue Impa \$1,514,400	acts for State and/	or Local Governmen	t (do not include in anni	ualized fiscal effect):
II.	Annualized Costs:			Annualized Fiscal im	pact on State funds from:
				Increased Costs	Decreased Costs
A.	State Costs by Category State Operations – Salaries	and Fringes		\$ 177,735	\$ -
	(FTE Position Changes)			(3.0 FTE)	(- FTE)
	State Operations – Other C	osts		2,000,000	
	Local Assistance				-
	Aids to Individuals or Orgar	nizations		32,018,000	-
	TOTAL State Costs by	Category		\$ 34,195,800	\$ -
B.	State Costs by Source of Fun	ds		Increased Costs	Decreased Costs
	GPR			\$ 11,559,500	\$ -
	FED			13,389,500	-
	PRO/PRS			9,246,900	-
	SEG/SEG-S				
•	State Revenues Complete this onl	y when proposal will inc x increase, decrease in	rease or decrease state	Increased Rev.	Decreased Rev.
	GPR Taxes			\$	\$ -
	GPR Earned			·	•
	FED				
	PRO/PRS			9,246,900	
	SEG/SEG-S				<u> </u>
	TOTAL State Revenue:	s		\$ 9,246,900	\$ -
		NET ANNUA	LIZED FISCAL IMP	ACT	LOCAL
NE	T CHANGE IN COSTS	\$	24,94	<u>\$</u>	
	T CHANGE IN REVENUES	\$		\$	I Date
Ri	epared By: / Phone # / Agency N chard T. Chao / 267-0356 HFS/OSF	ame	Authorized Signature John Klesow, 2	Geson	Z-29-00